

Author's Proof

Carefully read the entire proof and mark all corrections in the appropriate place, using the Adobe Reader commenting tools ([Adobe Help](#)). Do not forget to reply to the queries.

We do not accept corrections in the form of edited manuscripts.

In order to ensure the timely publication of your article, please submit the corrections within 48 hours.

If you have any questions, please contact microbiology.production.office@frontiersin.org.

Author Queries Form

Query No.	Details required	Author's Response
Q1	The citation and surnames of all of the authors have been highlighted. Please check all of the names carefully and indicate if any are incorrect. Please note that this may affect the indexing of your article in repositories such as PubMed.	
Q2	Confirm that the email address in your correspondence section is accurate.	
Q3	Please ask the following authors to register with Frontiers (at https://www.frontiersin.org/Registration/Register.aspx) if they would like their names on the article abstract page and PDF to be linked to a Frontiers profile. Please ensure to provide us with the profile link(s) when submitting the proof corrections. Non-registered authors will have the default profile image displayed. Lucia De Florio Annalisa Giona Etleva Dedej Marta Fogolari Silvia Spoto Gianguglielmo Zehender Massimo Ciccozzi	
Q4	If you decide to use previously published, copyrighted figures in your article, please keep in mind that it is your responsibility, as the author, to obtain the appropriate permissions and licenses and to follow any citation instructions requested by third-party rights holders. If obtaining the reproduction rights involves the payment of a fee, these charges are to be paid by the authors.	
Q5	Ensure that all the figures, tables and captions are correct.	
Q6	Verify that all the equations and special characters are displayed correctly.	
Q7	Ensure, if it applies to your study, the ethics statement is included in the article.	
Q8	Ensure to add all grant numbers and funding information, as after publication this is no longer possible.	

Query No.	Details required	Author's Response
Q9	We have changed the following references inside the text as per the reference list. Kindly confirm if this is fine. "Rice et al., 2008" as "Rice, 2010" "Stewart and Quirk, 2011" as "Stewart and Quirk, 2001" "Panopoulou et al., 2015" as "Panopoulou et al., 2010."	
Q10	Please include the following references in the reference list. Kalyan et al., 2016; Sidjabat et al., 2016.	
Q11	We have moved the web link appearing inside the text as footnote. Please confirm if this is fine.	
Q12	Inconsistent usage of the following terms (clades and sub-clades) here and elsewhere inside the text. Kindly advise. lb ₁ , lb ₂ , lb _{2a} , lb _{2b} , lb ₁ , lb _{2a} , and lb _{2b} ,	
Q13	Please cite "Chavda et al., 2016" inside the text.	



MALDI-TOF MS Identification and Clustering Applied to *Enterobacter* Species in Nosocomial Setting

Lucia De Florio¹, Elisabetta Riva², Annalisa Giona¹, Etleva Dedej¹, Marta Fogolari¹, Eleonora Cella³, Silvia Spoto⁴, Alessia Lai⁵, Gianguglielmo Zehender⁵, Massimo Ciccozzi³ and Silvia Angeletti^{1*}

¹ Unit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Rome, Italy, ² Unit of Virology, University Campus Bio-Medico of Rome, Rome, Italy, ³ Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italy, ⁴ Internal Medicine Department, University Campus Bio-Medico of Rome, Rome, Italy, ⁵ "L. Sacco" Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

OPEN ACCESS

Edited by:

Parag Vaishampayan,
Jet Propulsion Laboratory,
United States

Reviewed by:

Jorge Reinheimer,
National University of the Littoral,
Argentina

Spyridon Ntougias,
Democritus University of Thrace,
Greece

*Correspondence:

Silvia Angeletti
s.angeletti@unicampus.it

Specialty section:

This article was submitted to
Systems Microbiology,
a section of the journal
Frontiers in Microbiology

Received: 31 March 2018

Accepted: 26 July 2018

Published: xx August 2018

Citation:

De Florio L, Riva E, Giona A, Dedej E, Fogolari M, Cella E, Spoto S, Lai A, Zehender G, Ciccozzi M and Angeletti S (2018) MALDI-TOF MS Identification and Clustering Applied to *Enterobacter* Species in Nosocomial Setting. *Front. Microbiol.* 9:1885. doi: 10.3389/fmicb.2018.01885

Enterobacter microorganisms cause important bacterial infections in humans. Recently, carbapenem resistant isolates carrying the *blaKPC* gene were described and their clonal transmission in different nosocomial outbreaks reported. In this study, the relative numbers of *Enterobacter* species, their antimicrobial susceptibility along 3 years of observation and the identification ability of the two most common MALDI-TOF platforms were evaluated. A clustering analysis was performed to identify changes in the microbial population within the nosocomial environment. *Enterobacter* were identified using two platforms (MALDI-TOF Biotyper and VITEK MS). Antimicrobial susceptibility was tested by Vitek2 Compact and MIC₅₀ and MIC₉₀ was evaluated using GraphPad software. Clustering analysis was performed by MALDI-TOF and a dendrogram was built with both platforms and compared. The most frequent species isolated were *Enterobacter cloacae* and *Enterobacter aerogenes* with a gradual increase of *Enterobacter asburiae* in 2017. MALDI-TOF platforms showed a very good sensitivity and specificity except for *E. asburiae* identification that was reliable only by MALDI-TOF MS Biotyper. An increase of resistance for *Enterobacter*, confirmed by the isolation of extended spectrum beta-lactamase (ESBL) strains and the emergence of *E. cloacae* multidrug-resistant (MDR) and carbapenem resistant strains, was observed. A clonal route of transmission involving general surgery and geriatric wards was evidenced as previously described for *Klebsiella pneumoniae* MDR strains in the same nosocomial setting. These data represent an important source of information about the spreading of *Enterobacter* in the nosocomial environment.

Keywords: MALDI-TOF mass spectrometry, *Enterobacter*, resistance, nosocomial infection, clustering analysis

INTRODUCTION

Enterobacter species are gram-negative bacilli belonging to the family of Enterobacteriaceae and to the "ESKAPE" pathogens including *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species. This group of pathogens is the cause of important bacterial infections in humans

(Boucher et al., 2009; Rice, 2010). *Enterobacter cloacae* and *Enterobacter aerogenes* represent the most common *Enterobacter* species, even if other species such as *Enterobacter asburiae* have been identified as emergent pathogens causing severe infections (Brenner et al., 1986; Stewart and Quirk, 2001; Koth et al., 2012).

Enterobacter are intrinsically resistant to some antimicrobials, ampicillin and I and II generations cephalosporins, showing high ability to acquire resistance to most recent drugs, as cephalosporins of III and IV generations, carbapenems and aminoglycoside (Muyltjens and van der Ros-van de Repe, 1986; Leibovici et al., 1992). Recently, an increasing prevalence of multidrug-resistant (MDR) *Enterobacter* strains has been observed and in many cases nosocomial strains acquired carbapenemases as *bla*NDM-1 and *bla*KPC limiting the availability of appropriate antimicrobial treatments (Pottumarthy et al., 2003; Deshpande et al., 2006; Blanco et al., 2013). Moreover, these strains are frequently isolated in course of bloodstream infections and severe local infection as pneumonia, especially in critically ill patients (Fridkin, 2001; Marchaim et al., 2008; Castanheira et al., 2011). Given the presence of these two concomitant important factors, this group of pathogens is progressively receiving more attention in clinical practice for the challenge it poses today both to public health and to the management of the spread of infections within hospital environments (Hargreaves et al., 2015; Sidjabat et al., 2015; Zeng et al., 2016). The first *Enterobacter* strain carrying *bla*KPC gene was described in a septic patient in the year 2001 (Hossain et al., 2004). Since this first identification, sporadic cases as well as several outbreaks caused by resistant *Enterobacter* strains have been described worldwide (Bratu et al., 2005; Haraoui et al., 2013; Kiedrowski et al., 2014; Gomez-Simmonds et al., 2016). In recent surveillance studies on carbapenem resistant gram-negative strains, the isolates were represented primarily by *K. pneumoniae* and secondly by *Enterobacter* species carrying the *bla*KPC gene (Landman et al., 2011). The clonal dissemination of carbapenem resistant *Enterobacter* has been described in different nosocomial outbreaks, raising interest in the molecular epidemiology of these strains (Marchaim et al., 2011; Haraoui et al., 2013; Markovska et al., 2014; Villa et al., 2014). In a recent study, whole-genome sequencing was applied to *Enterobacter* clinical isolates from the United States, South America, and the Mediterranean region with the aim to increase knowledge on the genetic characteristics of these emerging pathogens. The study revealed that these strains, evolving from a unique ancestor, follow a clonal spread and that plasmids harboring *bla*KPC gene were horizontally transferred between strains (Kalyan et al., 2016).

In this study the relative numbers of *Enterobacter* species and the antimicrobial susceptibility of the strains isolated along 3 years of observation from 2015 to 2017 were evaluated. Moreover, the identification ability of the two most common MALDI-TOF platforms used in clinical setting was compared in a subgroup of nosocomial strains. In these strains, based on MALDI-TOF spectra peaks, a clustering analysis was performed to identify changes in the microbial population over time, or under the selective pressure of the nosocomial environment.

MATERIALS AND METHODS

Bacterial Isolates and Samples Collection

During the years 2015–2017, 445 strains of *Enterobacter* species have been isolated at the University Hospital Campus Bio-Medico of Rome, Italy. The species isolated and their relative number have been reported in **Table 1**, whereas the samples collected from the potential sites of infection has been described in **Table 2**. The study was performed using sample collected for the routine clinical diagnosis with the patient's consent.

Bacterial Identification

Bacterial identification was performed using the MALDI-TOF (Microflex LT, Bruker Daltonics, Germany) with the MALDI Biotyper 3.1 software version, and the MALDI-TOF VITEK MS-DS (bioMérieux, Marcy-l'Étoile, France), and the Saramis software.

MALDI-TOF MS Biotyper (Bruker, Daltonics, Germany) Identification

Bacterial colonies were grown overnight on sheep blood agar and subjected to according to the MALDI Biotyper protocol (Bruker Daltonics GmbH, Bremen, Germany). Each isolate was smeared for ten times onto target slide (Bruker Daltonics GmbH, Bremen, Germany) (Angeletti et al., 2015).

Spectra were acquired by the standard recommended method using the Biotyper preprocessing standard method and the Biotyper Main-Spectrum (MSP) identification standard method (2,000 to 20,000 Da; linear positive method; laser frequency of 60 Hz). Species were identified using the MALDI Biotyper 3.1 and its standard database (Bruker Taxonomy database version 3.3.1). The software automatically acquired spectra and analyzed them by standard pattern matching against the spectra of the species used as reference. After comparing the unknown spectra comparison with the reference spectra, the log scores were reported. Values higher than 1.9 were considered reliable for the identification at the species level whereas values ranging from 1.9 to 1.7 were required for reliable identification at the genus level.

MALDI-TOF VITEK MS v2.0 Identification (BioMérieux, Marcy-l'Étoile)

Strains subcultured on sheep blood agar plates (bioMérieux) at 37°C for 24 h were identified by the VITEK MS. Each

TABLE 1 | *Enterobacter* species and their relative number isolated from the year 2015 to the year 2017.

Year	<i>E. cloacae</i> n (%)	<i>E. aerogenes</i> n (%)	<i>E. asburiae</i> n (%)	Total n (%)
2015	84 (56)	60 (40)	7 (4)	151 (34)
2016	92 (62)	47 (32)	9 (6)	148 (33)
2017	105 (72)	26 (18)	15 (10)	146 (32)
Total n (%)	281 (63)	133 (30)	31 (7)	445 (100)

TABLE 2 | Source of *Enterobacter* isolates during the years 2015–2017: type of samples collected.

Year	Blood culture n (%)	Respiratory sample n (%)	Ulcer or wounds samples n (%)	Nasal/rectal swabs n (%)	Urine n (%)	Total n (%)
2015	20 (18)	11 (7)	68 (45)	16 (10)	36 (24)	151 (34)
2016	18 (12)	11 (7)	36 (24)	35 (24)	48 (32)	148 (33)
2017	18 (12)	7 (5)	64 (44)	18 (12)	39 (27)	146 (33)
Total n (%)	56 (12)	29 (6.5)	168 (38)	69 (15.5)	123 (28)	445 (100)

isolate was smeared for six times onto the VITEK MS-DS target slide (bioMérieux), supplied in a 48-well microscope slide format, and divided into three acquisition groups of 16 spots each using a 1 μ L disposable loop. The prepared samples were covered with 1 μ L of α -cyano-4-hydroxycinnamic acid (CHCA) matrix solution (bioMérieux) and dried at room temperature. The mass spectra were acquired using a VITEK MS Axima Assurance mass spectrometer (bioMérieux). The isolates were identified using the Advanced Spectrum Classifier (ASC) algorithm, comparing the obtained spectra with the typical spectra of each organism in the VITEK MS 1.1 database (which includes more than 25,000 spectra covering 585 species). For system calibration and internal identification control, *E. coli* ATCC 8739 was used. The VITEK MS v2.0 system is equipped with Shimadzu Axima Assurance mass spectrometer linked to a reference database, known as Knowledge Base. During analysis, spectra within a range of 2,000 to 20,000 Da are recorded in linear positive mode at a laser frequency of 50 Hz and for each analysis, laser shots at different positions within the target well produce up to 100 mass profiles that are summed into a single, raw mass spectrum. The spectrum is then processed by baseline correction and peak detected. Data are used to query the database to determine the taxonomic identity in form of single species-level identification. The result from the first test with the VITEK MS, which provided a single choice at species level with $\geq 90\%$ confidence, was used.

Antimicrobial Susceptibility Test and Antimicrobial Activity

Enterobacter antimicrobial susceptibility tests were performed by Vitek2 Compact (bioMérieux, Marcy-l'Étoile, France) and the resistant phenotype further confirmed with the Kirby-Bauer method according to Clinical Laboratory Standard Institute (CLSI) and European Committee for Antimicrobial Susceptibility Test (EUCAST) (Gherardi et al., 2012).

The antimicrobial activity of the compounds recommended by EUCAST has been evaluated for the most frequently isolated species of *Enterobacter* (*E. cloacae* and *E. aerogenes*) by MIC₅₀ and MIC₉₀ determination, using GraphPad software¹. The MIC₅₀ and MIC₉₀ have been calculated for 70 strains isolated in 2015 (44 *E. cloacae* and 26 *E. aerogenes*), for 62 strains in 2016 (45 *E. cloacae* and 17 *E. aerogenes*) and for 58 strains in 2017 (49 *E. cloacae* and 9 *E. aerogenes*).

¹ <https://www.graphpad.com/support/faq/fitting-bacterial-growth-data-to-determine-the-mic-and-nic/>

Clustering Analysis of MALDI-TOF MS Spectra

Spectra obtained for each isolate on MALDI-TOF MS Biotyper was loaded on ClinProTools by spectra grouping function, to allow grouping of all technical replicates in one biological replicate, named Class by the software. A Class dendrogram of all the study isolates was built using the ClinProTool dendrogram creation standard method (with the correlation distance measured by the average linkage algorithm) of the Biotyper 3.1 software (Bruker Daltonics, Germany). Clusters were consequently analyzed according to the arbitrary distance levels from 500 to 50.

Spectra obtained for each isolate on MALDI-TOF MS VITEK MS were compared each other by Saramis software analysis through which a hierarchical clustering of samples could be performed and the results represented as a dendrogram.

RESULTS

Bacterial Isolates

Four hundreds and forty-five strains of *Enterobacter* species have been isolated at the University Hospital Campus Bio-Medico of Rome, Italy, from the year 2015 to the year 2017. The number of strains isolated in each year was constant ranging from 151 isolates in the year 2015 to 148 and 146 in the year 2016 and 2017, respectively (Table 1). The species isolated and their relative number and percentage have been reported in Table 1. Along the 3 years of the study, the most frequent species was *E. cloacae* (63%) followed by *E. aerogenes* (30%) and *E. asburiae* (7%). The number of *E. cloacae* remained constant during the years whereas a decrease of *E. aerogenes* and a gradual increase of *E. asburiae* was observed in the year 2017 (Table 1).

The type of samples collected from the potential sites of infection have been reported in Table 2. The most frequent samples of origin were ulcers or wounds (38%) followed by urine (28%) and surveillance nasal or rectal swabs (15.5%). *Enterobacter* species were isolated in blood cultures in 12% of cases.

Enterobacter Identification by MALDI-TOF Platforms

Enterobacter strains were identified by two MALDI-TOF platforms and results compared, as reported in Table 1. The MALDI-TOF Biotyper system identified at the species level all isolate with a sensitivity of 100%. Strains were identified as

A

2015	AMC	AN	CAZ	CIP	CS	CTX	FEP	FOS	GM	IPM	MEM	SXT	TZP
MIC 50	32	2	1	0,5	0,5	1	1	32	1	0,5	0,25	20	4
MIC 90	32	2	64	0,75	0,5	64	2	256	1	1	0,25	320	128
2016	AMC	AN	CAZ	CIP	CS	CTX	FEP	FOS	GM	IPM	MEM	SXT	TZP
MIC 50	32	2	1	0,25	0,5	1	1	32	1	0,5	0,25	20	4
MIC 90	32	2	64	0,5	0,5	64	2	256	1	2	0,25	20	128
2017	AMC	AN	CAZ	CIP	CS	CTX	FEP	FOS	GM	IPM	MEM	SXT	TZP
MIC 50	32	2	1	0,25	0,5	1	1	32	1	0,5	0,25	20	4
MIC 90	32	4	64	4	0,5	64	2	256	16	2	0,25	320	128

Enterobacter cloacae

B

2015	AMC	AN	CAZ	CIP	CS	CTX	FEP	FOS	GM	IPM	MEM	SXT	TZP
MIC 50	32	2	1	0,25	0,5	1	1	16	1	0,5	0,25	20	4
MIC 90	32	2,6	30,4	0,5	0,5	15,2	1	64	1	2	0,25	20	128
2016	AMC	AN	CAZ	CIP	CS	CTX	FEP	FOS	GM	IPM	MEM	SXT	TZP
MIC 50	32	2	1	0,25	0,5	1	1	32	1	0,5	0,25	20	4
MIC 90	32	2	6,2	1,9	0,5	22	1	256	1	1	0,25	320	32
2017	AMC	AN	CAZ	CIP	CS	CTX	FEP	FOS	GM	IPM	MEM	SXT	TZP
MIC 50	32	2	1	0,25	0,5	1	1	32	1	0,5	0,25	20	4
MIC 90	32	16	64	1	0,5	64	2	256	1	2	0,25	20	32

Enterobacter aerogenes

FIGURE 1 | Antimicrobial activities in terms of MIC₅₀ and MIC₉₀ registered during the years 2015–2017 for *Enterobacter cloacae* (panel **A**) and *Enterobacter aerogenes* (panel **B**) isolates. Sensitive MIC (black color); Resistant MIC (red color); Intermedius MIC (blue color). AMC = amoxicillin-clavulanate; AN = Amikacin; CAZ = ceftazidime; CIP = ciprofloxacin; CS = colistin; CTX = Cefotaxime; FEP = Cefepime; FOS = Fosfomycin; GM = Gentamicin; IPM = Imipenem; MEM = meropenem; SXT = Trimethoprim/Sulfamethoxazole; TZP = piperacillin-tazobactam. Numbers indicate the MICs values.

TABLE 3 | ESBL *Enterobacter* strains isolated from the year 2015 to the year 2017.

Year	ESBL <i>E. cloacae</i> strains n/total (%)	ESBL <i>E. aerogenes</i> strains n/total (%)	ESBL <i>E. asburiae</i> strains n/total (%)	Total n/total (%)
2015	23/84 (27)	18/60 (30)	1/7 (4)	42/151 (28)
2016	20/92 (22)	16/47 (34)	2/9 (22)	38/148 (26)
2017	36/105 (34)	7/26 (27)	8/15 (53)	51/146 (35)
Total n/total (%)	79/281 (28)	41/133 (31)	11/31 (35)	131/445 (29)

E. cloacae in 281/445 (63%) of isolates, as *E. aerogenes* in 133/445 (30%) isolates and as *E. asburiae* in 31/445 (7%) isolates.

The MALDI-TOF VITEK MS system correctly identified *E. aerogenes* and *E. cloacae* isolates except in two cases (2 strains of *E. cloacae* were not identified), whereas failed to identify all *E. asburiae* strains. Globally the identification at the species level was not achieved in 33/445 isolates (7.5%) corresponding to a sensitivity of 92.5%.


Antimicrobial Activity and Antimicrobial Susceptibility Test

The antimicrobial activities expressed in terms of MIC₅₀ and MIC₉₀ registered during the years 2015–2017 for *E. cloacae* and *E. aerogenes* have been represented in **Figure 1**. *Enterobacter* species are intrinsically resistant to ampicillin and cephalosporins of I and II generation. Regarding other antimicrobials, MIC₅₀ was sensitive for both species except in case of Cefoxitin and trimethoprim/sulfamethoxazole. The MIC₉₀ revealed the resistance for both species to cephalosporins of III and IV generation and piperacillin/tazobactam all over the 3 years of observation. Furthermore, the emergence of resistance to fluoroquinolones and aminoglycoside for both species was evidenced in the year 2017 (**Figure 1**).

Extended Spectrum Beta-Lactamase (ESBL) *Enterobacter* strains have been isolated along the 3 years of the study. A total of 131/445 (29%) isolates resulted ESBL, as reported in **Table 3**. The ESBL phenotype was identified in all three species of *Enterobacter* exactly in 79/281 (28%) *E. cloacae*, in 41/133 (31%) *E. aerogenes* and in 11/31 (35%) *E. asburiae* (**Table 3**). In the year 2017, 2/105 (1.9%) *E. cloacae* strains resulted MDR and carbapenem resistant. For these two strains, the carbapenem resistance was analysed by real-time PCR (GeneXpert Carba-R Assay, Cepheid® Inc.) for the following *blaKPC* (KPC), *blaNDM* (NDM), *blaVIM* (VIM), *blaOXA-48* (OXA-48), and *blaIMP-1* (IMP-1) gene sequences. *blaIMP-1* in one strain and *blaVIM* genes in the other, were detected.

Clustering Analysis of MALDI-TOF MS Spectra

The class dendrogram of all *Enterobacter* isolates built by the ClinProTool dendrogram creation standard method using the Biotyper 3.1 software (Bruker Daltonics, Germany) revealed two major clusters (I,II) according to an arbitrary cut-off located at the distance level of 500 (**Figure 2**). In each cluster, distinct clades are evident. Cluster I, includes clades Ia and Ib further distinguished in the sub-clades I_{b1} and I_{b2}. The sub-clade



I_{b2} further includes the sub-clades Ib_{2a} and Ib_{2b}. In cluster I all *E. cloacae* and *E. asburiae* strains are included, exactly *E. asburiae* isolates form a separate group represented in the sub-clade Ib₂, whereas all *E. cloacae* strains are distributed in the other clades and sub-clades of the cluster I (Figure 2). Cluster II includes all *E. aerogenes* strains distributed in two different clades (IIa and IIb). Within cluster I and II, strains isolated in patients admitted to general surgery and geriatric wards are located in the same clade or sub-clade separately from strains isolated in other hospital wards. In cluster I, the clade Ia includes only *E. cloacae* strains from general surgery and geriatric wards; in clade Ib general surgery and geriatric isolates are always grouped in the same sub-clades (Ib₁, Ib_{2b}) and in the sub-clade Ib_{2a} are recovered the two MDR isolates. Interestingly, in the sub-clade Ib_{2a} also *E. asburiae* strains are all from patients admitted in these two wards.

The class dendrogram of all *Enterobacter* isolates built by VITEK MS Saramis software, showed two major clusters I and II. Cluster I including *E. cloacae* strains and cluster II including *E. aerogenes* strains. In cluster I and cluster II, two different sub-clades are evident [Ia, Ib, IIa, and IIb (Figure 3)]. A distinct clade or sub-clade for *E. asburiae* strains is not represented, in fact these strains are identified as *Enterobacter* spp., even if these strains are located within the cluster I, distributed within the clades Ia and Ib including *E. cloacae* isolates.

In the clades Ia and Ib *E. cloacae* and *E. asburiae* isolates from general surgery and geriatric wards are included in the same clade or sub-clades separately from strains of others wards. In the clade II, *E. aerogenes* strains are distributed in two clades IIa and IIb, exactly strains isolated in general surgery and geriatric wards are represented in clade IIa whereas strains from other wards are grouped in clade IIb (Figure 3).

DISCUSSION

The study of the microbial ecology is fundamental in the era of antimicrobial resistance. Recently, the environment has been suggested as source and way of dissemination of resistance, recognizing to the environmental bacteria as well as to the different human microbiomes an important role (Martínez, 2008; Wright, 2010; Ashbolt et al., 2013; Finley et al., 2013; Pruden et al., 2013).


Resistant microorganism is rapidly evolving under the selective pressure exerted in the different environment where the microorganism is adapting.

The nosocomial setting represents a fertile environment where microorganism can rapidly evolve acquiring mobile genetic elements conferring antimicrobial resistance and where their spreading is the cause of fearsome infections.

The rapid identification of bacterial strains causing nosocomial infections, the knowledge of the resistance patterns and of the clonal dissemination pathway in the specific environment can represent an advantage especially in terms of morbidity, mortality and health costs savings.

In this study, the identification of *Enterobacter* pathogens circulating within the hospital setting and their antimicrobial susceptibility along 3 years of observation from 2015 to 2017 has been evaluated to have a picture of the circulation of these pathogens rapidly acquiring resistance to important antibiotics such as carbapenems. To gain deep knowledge about the circulation of these strains, a clustering analysis based on MALDI-TOF spectra was performed and the relationship existing between the isolates or any potential case of clonal transmission analyzed.

Based on the results obtained we could observe that the most frequent species isolated were *E. cloacae* and *E. aerogenes* with



a gradual increase of *E. asburiae* in 2017, a species recently recognized as cause of severe infections (Brenner et al., 1986; Stewart and Quirk, 2001; Koth et al., 2012). The increasing circulation of the *E. asburiae* strains in the year 2017 in the nosocomial setting confirms the general increase observed in other settings and the potential enrollment as cause of clinically significant infections. Furthermore, the spreading of these emerging strains in the nosocomial setting predisposed to the rapid acquisition of antimicrobial resistance under the selective pressure of the antimicrobial compounds use. Noteworthy, to the consistent increase of *E. asburiae* strains corresponded an increase in the ESBL resistance phenotype that was evidenced in about 53% of the strains isolated in the year 2017.

The *Enterobacter* strains identification was based on MALDI-TOF platforms, recently introduced in the routine of the clinical microbiology laboratory for its rapidity and cost-effectiveness (Angeletti, 2017). The identification was simultaneously performed by the two most frequently used MALDI-TOF platforms and their performance compared. Both

instruments showed a very good sensitivity and specificity except for *E. asburiae* identification that was reliable only using one of this, MALDI-TOF MS Biotyper. In fact in case of MALDI-TOF VITEK MS the two species *E. cloacae* and *E. asburiae* were grouped together and identified as a low discrimination result. This is in line with the observation that the ability of identification and discrimination between different species depends on the completeness of the database used for spectra matching after acquisition and its updating (Angeletti, 2017).

Regarding antimicrobial susceptibility expressed in term of MIC₅₀ and MIC₉₀ registered during the years 2015–2017, a raise of the MIC₉₀ for cephalosporins of III and IV generation, piperacillin/tazobactam, fluoroquinolones and aminoglycoside was detected suggesting an increase of resistance for these antimicrobials under the selective pressure of the nosocomial environment. This was also confirmed by the isolation of ESBL strains for all three species, *E. cloacae*, *E. aerogenes*, and *E. asburiae* and by the emergence within the nosocomial setting in the year 2017 of *E. cloacae* MDR and carbapenem resistant

685 strains. These data are in agreement with other studies suggesting
686 the evidence of isolates carrying important determinants of
687 carbapenem resistance such as *bla*IMP and *bla*VIM (Panopoulou
688 et al., 2010; Sidjabat et al., 2016). These *Enterobacter* strains play
689 an important role in nosocomial infections where carbapenems
690 represent an important therapeutic option especially in case of
691 systemic severe infections (Pottumarthy et al., 2003; Deshpande
692 et al., 2006; Blanco et al., 2013). The rapid identification of
693 these strains, the antimicrobial susceptibility and the resistant
694 phenotype characterization together with the strict surveillance
695 of the MDR strains are major concerns to limit the further
696 spreading of these fearsome pathogens within the nosocomial
697 setting.

698 The clustering dendrograms built on the basis of the spectra
699 applying mathematics algorithm, showed two major clusters by
700 both MALDI-TOF clustering analysis. These clusters included
701 distinct clades or sub-clades where strains isolated from general
702 surgery and geriatric wards were separated from strains of
703 others wards. Interestingly, the clustering realized on the spectra
704 similarity evidenced that those strains circulating in the general
705 surgery and geriatrics wards were more strictly correlated than
706 others isolated in different wards. A potential clonal route of
707 transmission preferentially between these two wards could be
708 suggested. This clonal route of transmission is in agreement
709 with our previous studies performed in the same nosocomial
710 setting but involving other gram-negative pathogens such as
711 *K. pneumoniae* MDR strains (Angeletti et al., 2016; Cella et al.,
712 2017). In these studies, gram-negative MDR strains causing
713 nosocomial infections moved from the general surgery to the
714 geriatric wards and, following this route, reached other patients
715 in other hospital wards. The MALDI-TOF clustering applied

742 to the *Enterobacter* spp. strains causing nosocomial infections
743 within the same hospital setting confirmed the existence of
744 this preferential way of transmission for gram-negative bacteria,
745 probably as a consequence of the diagnostic and invasive
746 procedure that are commonly used in these wards.
747

748 CONCLUSION

749 The results of this study on *Enterobacter* pathogen, able to
750 acquire determinant of resistance as non-metallo-carbapenemase
751 class A carbapenemase (Blanco et al., 2013; Kalyan et al.,
752 2016) as well as *K. pneumoniae*, suggest that the selective
753 pressure existing in the nosocomial setting and the surgical or
754 diagnostic procedure performed could influence the microbial
755 ecology of the gram-negative pathogens. These findings represent
756 an important source of information about the spreading of
757 *Enterobacter*, an emergent pathogen for its ability to acquire
758 determinants of antimicrobial resistance. Preventive measures
759 based on active microbiological surveillance are needed to limit
760 the dissemination of these microorganisms and guarantee the
761 health status in the nosocomial environment.
762

763 AUTHOR CONTRIBUTIONS

764 LDF, ER, MC, and SA conceived and designed the study. LDF,
765 AG, ED, SS, and MF collected the samples. LDF, AG, ED, MF, EC,
766 and SA performed the experiments. LDF, ER, SS, MC, AS, AL,
767 and GZ analyzed the data and wrote the paper. All authors read,
768 reviewed, and approved the final manuscript.
769

770 REFERENCES

- 771 Angeletti, S. (2017). Matrix assisted laser desorption time of flight mass
772 spectrometry (MALDI-TOF MS) in clinical microbiology. *J. Microbiol. Method*
773 138, 20–29. doi: 10.1016/j.mimet.2016.09.003
- 774 Angeletti, S., Dicuonzo, G., Avola, A., Crea, F., Dedej, E., Vailati, F., et al. (2015).
775 Viridans group Streptococci clinical isolates: MALDI-TOF mass spectrometry
776 versus gene sequence-based identification. *PLoS One* 10:e0120502. doi: 10.1371/
777 journal.pone.0120502
- 778 Angeletti, S., Presti, A. L., Cella, E., Fogolari, M., De Florio, L., and Dedej, E., et al.
779 (2016). *Klebsiella pneumoniae* blaKPC-3 nosocomial epidemic: Bayesian and
780 evolutionary analysis. *Infect. Genet. Evol.* 46, 85–93. doi: 10.1016/j.meegid.2016.
781 10.031
- 782 Ashbolt, N. J., Amézquita, A., Backhaus, T., Borriello, P., Brandt, K. K.,
783 Collignon, P., et al. (2013). Human health risk assessment (HHRA) for
784 environmental development and transfer of antibiotic resistance. *Environ.*
785 *Health Perspect.* 121, 993–1001. doi: 10.1289/ehp.1206316
- 786 Blanco, V. M., Rojas, L. J., De La Cadena, E., Maya, J. J., Camargo, R. D., Correa, A.,
787 et al. (2013). First report of a non metallo-carbapenemase class A carbapenemase
788 in *Enterobacter cloacae* isolate from Colombia. *Antimicrob. Agents Chemother.*
789 57:3457. doi: 10.1128/AAC.02425-12
- 790 Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B.,
791 et al. (2009). Bad bugs, no drugs: no ESKAPE! An update from the infectious
792 diseases society of America. *Clin. Infect. Dis.* 48, 1–12. doi: 10.1086/595011
- 793 Bratu, S., Landman, D., Alam, M., Tolentino, E., and Quale, J. (2005). Detection
794 of KPC carbapenem-hydrolyzing enzymes in *Enterobacter* spp. from Brooklyn,
795 New York. *Antimicrob. Agents Chemother.* 49, 776–778. doi: 10.1128/AAC.49.
796 2.776-778.2005

- 797 Brenner, D. J., McWhorter, A. C., Kai, A., Steigerwalt, A. G., and Farmer,
798 J. J. III (1986). *Enterobacter asburiae* sp. nov., a new species found in
799 clinical specimens, and reassignment of *Erwinia dissolvens* and *Erwinia*
800 *nimipressuralis* to the genus *Enterobacter* as *Enterobacterdissolvens* comb. nov.
801 and *Enterobacter nimipressuralis* comb. nov. *J. Clin. Microbiol.* 23, 1114–1120.
802
- 803 Castanheira, M., Deshpande, L. M., Mathai, D., Bell, J. M., Jones, R. N., and
804 Mendes, R. E. (2011). Early dissemination of NDM-1- and OXA-181-producing
805 Enterobacteriaceae in Indian hospitals: report from the SENTRY antimicrobial
806 surveillance program, 2006–2007. *Antimicrob. Agents Chemother.* 55, 1274–
807 1278. doi: 10.1128/AAC.01497-10
- 808 Cella, E., Ciccozzi, M., Lo Presti, A., Fogolari, M., Azarian, T., Prosperi, M.,
809 et al. (2017). Multi-drug resistant *Klebsiella pneumoniae* strains circulating in
810 hospital setting: whole-genome sequencing and Bayesian phylogenetic analysis
811 for outbreak investigations. *Sci. Rep.* 7:3534. doi: 10.1038/s41598-017-03581-4
- 812 Chavda, K. D., Chen, L., Fouts, D. E., Sutton, G., Brinkac, L., Jenkins, S. G.,
813 et al. (2016). Comprehensive genome analysis of carbapenemase-producing
814 *Enterobacter* spp.: new insights into phylogeny, population structure, and
815 resistance mechanisms. *mBio.* 7:e02093-16. doi: 10.1128/mBio.02093-16
- 816 Deshpande, L. M., Jones, R. N., Fritsche, T. R., and Sader, H. S. (2006). Occurrence
817 and characterization of carbapenemase-producing Enterobacteriaceae: report
818 from the sentry antimicrobial surveillance program (2000–2004). *Microb. Drug*
819 *Resist.* 12, 223–230. doi: 10.1089/mdr.2006.12.223
- 820 Finley, R. L., Collignon, P., Larsson, D. G., McEwen, S. A., Li, X. Z., Gaze, W. H.,
821 et al. (2013). The scourge of antibiotic resistance: the important role of the
822 environment. *Clin. Infect. Dis.* 57, 704–710. doi: 10.1093/cid/cit355
- 823 Fridkin, S. K. (2001). Increasing prevalence of antimicrobial resistance in intensive
824 care units. *Crit. Care Med.* 29(4 suppl.), N64–N68. doi: 10.1097/00003246-
825 200104001-00002

Q13

- 799 Gherardi, G., Angeletti, S., Panitti, M., Pompilio, A., Di Bonaventura, G., Crea, F.,
800 et al. (2012). Comparative evaluation of the Vitek-2 compact and phoenix
801 systems for rapid identification and antibiotic susceptibility testing directly
802 from blood cultures of gram-negative and gram-positive isolates. *Diagn.*
803 *Microbiol. Infect. Dis.* 72, 20–31. doi: 10.1016/j.diagmicrobio.2011.09.015
- 804 Gomez-Simmonds, A., Hu, Y., Sullivan, S. B., Wang, Z., Whittier, S., and
805 Uhlemann, A. C. (2016). Evidence from a New York city hospital of rising
806 incidence of genetically diverse carbapenem-resistant *Enterobacter cloacae* and
807 dominance of ST171, 2007–14. *J. Antimicrob. Chemother.* 71, 2351–2353. doi:
808 10.1093/jac/dkw132
- 809 Haraoui, L. P., Lévesque, S., Lefebvre, B., Blanchette, R., Tomkinson, M.,
810 Mataseje, L., et al. (2013). Polyclonal outbreak of KPC-3-producing
811 *Enterobacter cloacae* at a single hospital in Montreal, Quebec, Canada. *J. Clin.*
812 *Microbiol.* 51, 2406–2408. doi: 10.1128/JCM.02480-12
- 813 Hargreaves, M. L., Shaw, K. M., Dobbins, G., Snippes Vagnone, P. M., Harper, J. E.,
814 et al. (2015). Clonal dissemination of *Enterobacter cloacae* harboring bla_{KPC-3}
815 in the upper midwestern United States. *Antimicrob. Agents Chemother.* 59,
816 7723–7734. doi: 10.1128/AAC.01291-15
- 817 Hossain, A., Ferraro, M. J., Pino, R. M., Dew, R. B. III, Moland, E. S., Lockhart,
818 T. J., et al. (2004). Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-
819 2 in an *Enterobacter* sp. *Antimicrob. Agents Chemother.* 48, 4438–4440. doi:
820 10.1128/AAC.48.11.4438-4440.2004
- 821 Kiedrowski, L. M., Guerrero, D. M., Perez, F., Viau, R. A., Rojas, L. J., Mojica, M. F.,
822 et al. (2014). Carbapenem resistant *Enterobacter cloacae* isolates producing
823 KPC-3, North Dakota, USA. *Emerg. Infect. Dis.* 20, 1583–1585. doi: 10.1128/
824 AAC.01291-15
- 825 Koth, K., Boniface, J., Chance, E. A., and Hanes, M. C. (2012). *Enterobacter asburiae*
826 and *Aeromonas hydrophila*: soft tissue infection requiring debridement.
827 *Orthopedics* 35, e996–e999. doi: 10.3928/01477447-20120525-52
- 828 Landman, D., Salamera, J., Singh, M., and Quale, J. (2011). Accuracy of carbapenem
829 nonsusceptibility for identification of KPC-possessing Enterobacteriaceae by
830 use of the revised CLSI breakpoints. *J. Clin. Microbiol.* 49, 3931–3933. doi:
831 10.1128/JCM.01176-11
- 832 Leibovici, L., Wysenbeek, A. J., Konisberger, H., Samra, Z., Pitlik, S. D., and
833 Drucker, M. (1992). Patterns of multiple resistance to antibiotics in gram-
834 negative bacteria demonstrated by factor analysis. *Eur. J. Clin. Microbiol. Infect.*
835 *Dis.* 11, 782–788. doi: 10.1007/BF01960876
- 836 Marchaim, D., Chopra, T., Perez, F., Hayakawa, K., Lephart, M. P. R.,
837 Bheemreddy, S., et al. (2011). Outcomes and genetic relatedness of carbapenem-
838 resistant *Enterobacteriaceae* at Detroit Medical Center. *Infect. Control Hosp.*
839 *Epidemiol.* 32, 861–871. doi: 10.1086/661597
- 840 Marchaim, D., Navon-Venezia, S., Schwaber, M. J., and Carmeli, Y. (2008).
841 Isolation of imipenem-resistant *Enterobacter* species: emergence of KPC-
842 2 carbapenemase, molecular characterization, epidemiology, and outcomes.
843 *Antimicrob. Agents Chemother.* 52, 1413–1418. doi: 10.1128/AAC.01103-07
- 844 Markovska, R. D., Stoeva, T. J., Bojkova, K. D., and Mitov, I. G. (2014).
845 Epidemiology and molecular characterization of extended-spectrum beta-
846 lactamase-producing *Enterobacter* spp., *Pantoea agglomerans*, and *Serratia*
847 *marcescens* isolates from a Bulgarian hospital. *Microb. Drug Resist.* 20, 131–137.
848 doi: 10.1089/mdr.2013.0102
- 849
850
851
852
853
854
855
- Martínez, J. L. (2008). Antibiotics and antibiotic resistance genes in natural
environments. *Science* 321, 365–367. doi: 10.1126/science.1159483
- Muytjens, H. L., and van der Ros-van de Repe, J. (1986). Comparative
in vitro susceptibilities of eight enterobacter species, with special reference to
Enterobacter sakazakii. *Antimicrob. Agents Chemother.* 29, 367–370. doi: 10.
1128/AAC.29.2.367
- Panopoulou, M., Alepopoulou, E., Ikonomidis, A., Grapsa, A., Paspalidou, E., and
Kartali-Ktenidou, S. (2010). Emergence of VIM-12 in *Enterobacter cloacae*.
J. Clin. Microbiol. 48, 3414–3415. doi: 10.1128/JCM.00843-10
- Pottumarthy, S., Moland, E. S., Juretschko, S., Swanzy, S. R., Thomson, K. S., and
Fritsche, T. R. (2003). NmcA carbapenem-hydrolyzing enzyme in *Enterobacter*
cloacae in North America. *Emerg. Infect. Dis.* 9, 999–1002. doi: 10.3201/eid0908.
030096
- Pruden, A., Larsson, D. G. J., Amézquita, A., Collignon, P., Brandt, K. K., Graham,
D. W., et al. (2013). Management options for reducing the release of antibiotics
and antibiotic resistance genes to the environment. *Environ. Health Perspect.*
121, 878–885. doi: 10.1289/ehp.1206446
- Rice, L. B. (2010). Progress and challenges in implementing the research on
ESKAPE pathogens. *Infect. Control Hosp. Epidemiol.* 31(Suppl. 1), S7–S10. doi:
10.1086/655995
- Sidjabat, H. E., Townell, N., Nimmo, G. R., George, N. M., Robson, J., Vohra, R.,
et al. (2015). Dominance of IMP-4-producing *Enterobacter cloacae* among
carbapenemase producing *Enterobacteriaceae* in Australia. *Antimicrob. Agents*
Chemother. 59, 4059–4066. doi: 10.1128/AAC.04378-14
- Stewart, J. M., Quirk, J. R. (2001). Community-acquired pneumonia caused by
Enterobacter asburiae. *Am. J. Med.* 111, 82–83. doi: 10.1016/S0002-9343(01)
00791-4
- Villa, J., Viedma, E., Brañas, P., Orellana, M. A., Otero, J. R., and Chaves, F.
(2014). Multiclonal spread of VIM-1-producing *Enterobacter cloacae* isolates
associated with In624 and In488 integrons located in an IncHI2 plasmid.
Int. J. Antimicrob. Agents 43, 451–455. doi: 10.1016/j.ijantimicag.2014.
02.006
- Wright, G. D. (2010). Antibiotic resistance in the environment: a link to the clinic?
Curr. Opin. Microbiol. 13, 589–594. doi: 10.1016/j.mib.2010.08.005
- Zeng, K. J., Doi, Y., Patil, S., Huang, X., and Tian, G. B. (2016). Emergence of
the plasmid-mediated *mcr-1* gene in colistin resistant *Enterobacter aerogenes*
and *Enterobacter cloacae*. *Antimicrob. Agents Chemother.* 60, 3862–3863. doi:
10.1128/AAC.00345-16

Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.

Copyright © 2018 De Florio, Riva, Giona, Dedej, Fogolari, Cella, Spoto, Lai,
Zehender, Ciccoczi and Angeletti. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.